Publications
Publications of Artery Compounds
Molina-Gonzalez I, Holloway RK, Jiwaji Z, Dando O, Kent SA, Emelianova K, Lloyd AF, Forbes LH, Mahmood A, Skripuletz T, Gudi V, Febery JA, Johnson JA, Fowler JH, Kuhlmann T, Williams A, Chandran S, Stangel M, Howden AJM, Hardingham GE, Miron VE.
Astrocyte-oligodendrocyte interaction regulates central nervous system regeneration.
Nat Commun. 2023 June. PMID: 37291151.
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys.
Alz Res Therapy. 2022 June. PMID: 35751102.
Proc Natl Acad Sci U S A. 2021 December. PMID: 34949639.
ApoE4 Alters ABCA1 Membrane Trafficking in Astrocytes.
Journal of Neuroscience. 2019 November. PMID: 31641056.
Voskuhl RR, Itoh N, Tassoni A, Matsukawa MA, Ren E, Tse V, Jang E, Suen TT, Itoh Y.
Proc Natl Acad Sci U S A. 2019 May. PMID: 31040210.
Hafiane A, Johansson J, Genest J.
Canadian Journal of Cardiology. 2018 February. PMID: 31151713.
Azhar S, Bittner S, Hu J, Shen WJ, Cortez Y, Hao X, Lu H, Lagerstedt JO, Kraemer FB, Johansson JO.
Novel ABCA1 peptide agonists with antidiabetic action.
Mol Cell Endocrinol. 2018 October. PMID: 30290217.
Clin Hypertens. 2018 September. PMID: 30237900.
Proc Natl Acad Sci U S A. 2018 January. PMID: 29279367.
Differential Effects of apoE4 and Activation of ABCA1 on Brain and Plasma Lipoproteins.
PLoS One. 2016 November. PMID: 27824936.
Boehm-Cagan A, Bar R, Liraz O, Bielicki JK, Johansson JO, Michaelson DM.
ABCA1 Agonist Reverses the ApoE4-Driven Cognitive and Brain Pathologies.
J Alzheimers Dis. 2016 August. PMID: 27567858.
ABCA1 agonist peptides for the treatment of disease.
Curr Opin Lipidol. 2016 February. PMID: 26655293.
Hafiane A, Bielicki JK, Johansson J, Genest J.
Novel Apo E-Derived ABCA1 Agonist Peptide (CS-6253) Promotes Reverse Cholesterol Transport and Induces Formation of preβ-1 HDL In Vitro.
PLoS One. 2015 July. PMID: 26207756.
Hafiane A, Bielicki JK, Johansson J, Genest J.
Biochim Biophys Acta. 2014 October. PMID: 25091998.
Zheng Y, Patel AB, Narayanaswami V, Bielicki JK.
Retention of α-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency.
Biochem Biophys Res Commun. 2013 November. PMID: 24129191.
Zheng Y, Patel AB, Narayanaswami V, Hura GL, Hang B, Bielicki JK.
HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution.
Biochemistry. 2011 May. PMID: 21476522.
Bielicki JK, Zhang H, Cortez Y, Zheng Y, Narayanaswami V, Patel A, Johansson J, Azhar S.
J Lipid Res. 2010 June. PMID: 20075422.
Supporting Publications
Supporting publications of ABCA1 and neurodegenerative, diabetes, and cardiovascular disease
Yassine HN, Feng Q, Chiang J, Petrosspour LM, Fonteh AN, Chui HC, Harrington MG.
J Am Heart Assoc. 2016 Feb 12;5(2). pii: e002886. PMID: 26873692.
Nordestgaard LT, Tybjærg-Hansen A, Nordestgaard BG, Frikke-Schmidt R.
Loss-of-function mutation in ABCA1 and risk of Alzheimer's disease and cerebrovascular disease.
Alzheimers Dement. 2015 Dec;11(12):1430-8. PMID: 26079414.
Kim SH, Kothari S, Patel AB, Bielicki JK, Narayanaswami V.
A pyrene based fluorescence approach to study conformation of apolipoprotein E3 in macrophage-generated nascent high density lipoprotein.
Biochem Biophys Res Commun. 2014 Jul 18;450(1):124-8. PMID: 24866239.
Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, Zhang J, Lampe J, Craft S.
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.
JAMA Neurol. 2013 Aug;70(8):972-80. PMID: 23779114.
Zheng Y, Kim SH, Patel AB, Narayanaswami V, Iavarone AT, Hura GL, Bielicki JK.
The positional specificity of EXXK motifs within an amphipathic α-helix dictates preferential lysine modification by acrolein: implications for the design of high-density lipoprotein mimetic peptides.
Biochemistry. 2012 Aug 14;51(32):6400-12. PMID: 22800301.
Vedhachalam C, Narayanaswami V, Neto N, Forte TM, Phillips MC, Lund-Katz S, Bielicki JK.
The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins.
Biochemistry. 2007 Mar 13;46(10):2583-93. PMID: 17305370.
Natarajan P, Forte TM, Chu B, Phillips MC, Oram JF, Bielicki JK.
Identification of an apolipoprotein A-I structural element that mediates cellular cholesterol efflux and stabilizes ATP binding cassette transporter A1.
J Biol Chem. 2004 Jun 4;279(23):24044-52. PMID: 15051721.
Jia Z, Natarajan P, Forte TM, Bielicki JK.
Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-I(Milano).
Biochem Biophys Res Commun. 2002 Sep 20;297(2):206-13. PMID: 12237103.
Bielicki JK, Oda MN.
Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I.
Biochemistry. 2002 Feb 12;41(6):2089-96. PMID: 11827556.
Bielicki JK, McCall MR, Forte TM.
Apolipoprotein A-I promotes cholesterol release and apolipoprotein E recruitment from THP-1 macrophage-like foam cells.
J Lipid Res. 1999 Jan;40(1):85-92. PMID: 9869653.
Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, Segrest JP, Phillips MC, Rothblat GH.
Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides.
Biochemistry. 1995 Jun 20;34(24):7955-65. PMID: 7794908.
Forte TM, Bielicki JK, Goth-Goldstein R, Selmek J, McCall MR.